IGFBP2 and cancer: The decreasing of adiponectin also reduced the synthesizing of insulin-like growth factor binding protein 1 (IGFBP1) and insulin-like growth factor binding protein 2 (IGFBP2) in the liver, thereby increasing bioavailability of insulin-like growth factor 1 (IGF1), and contributing to cancer development [16].